Use of Specific Genetic Alteration s of Tumoral Cells Identified by NGS to Follow Peripheral Samples of Children With Metastatic and/or High Risk Solid Tumor -
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Metastatic and/or High Risk Solid Tumor of Children
- Sponsor
- Institut Curie
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Detection by Polymerase Chain Reaction (PCR) of specific genetic alterations
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The search for genetic alterations in primary tumor by NGS techniques followed by the detection of these alterations in circulating tumor DNA and/or CTC/DTC present in peripheral samples (blood, cerebrospinal fluid, bone marrow, possibly urine) collected during several steps and after the treatment could be a tool to monitor the response during and after the treatment.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Children with metastatic and/or high risk solid tumor, of the following pathologies :
- •Neuroblastoma, sarcoma, malignant brain tumor (medulloblastoma, high-grade glioma), bone tumors, rhabdoid tumors, others rare tumors
- •Availability of a frozen tumoral sample (primary tumor or metastasis whatever the localization) at diagnosis allowing analysis of genetic alterations by a NGS technique
- •Age \< 18 years
- •Signed informed consent by parents or legal representatives
- •Patient having health care insurance
- •Exclusion Criteria :
- •Age ≥ 18 years
- •No signed informed consent by parents or legal representatives
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Detection by Polymerase Chain Reaction (PCR) of specific genetic alterations
Time Frame: at the inclusion
Genetic alterations which have been previously detected by NGS technique in the tumor, in circulating tumoral DNA and/or CTC/DTC present in a blood sample at the inclusion.
Detection of specific genetic alterations of tumoral cells in peripheral samples
Time Frame: Up to 6 years
Detection of specific genetic alterations of tumoral cells in peripheral samples for which presence of tumoral cells has been confirmed by conventional clinic techniques (cytology, anatomopathology, immunohistochemistry
Secondary Outcomes
- Change of CTC/DTC/circulating tumoral DNA levels detected by PCR targeting specific genetic alterations of tumoral cells in peripheral samples will be confronted to clinical features including patient outcome(Up to 6 years)
- Detection of genetic alterations in solid tumor pediatric samples(At the inclusion)